Cargando…

Mitochondria-Targeted Delivery of Camptothecin Based on HPMA Copolymer for Metastasis Suppression

Poor anti-metastasis effects and side-effects remain a challenge for the clinical application of camptothecin (CPT). Mitochondria can be a promising target for the treatment of metastatic tumors due to their vital roles in providing energy supply, upregulating pro-metastatic factors, and controlling...

Descripción completa

Detalles Bibliográficos
Autores principales: Yi, Xiaoli, Yan, Yue, Shen, Xinran, Li, Lian, Huang, Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331251/
https://www.ncbi.nlm.nih.gov/pubmed/35893790
http://dx.doi.org/10.3390/pharmaceutics14081534
_version_ 1784758355991986176
author Yi, Xiaoli
Yan, Yue
Shen, Xinran
Li, Lian
Huang, Yuan
author_facet Yi, Xiaoli
Yan, Yue
Shen, Xinran
Li, Lian
Huang, Yuan
author_sort Yi, Xiaoli
collection PubMed
description Poor anti-metastasis effects and side-effects remain a challenge for the clinical application of camptothecin (CPT). Mitochondria can be a promising target for the treatment of metastatic tumors due to their vital roles in providing energy supply, upregulating pro-metastatic factors, and controlling cell-death signaling. Thus, selectively delivering CPT to mitochondria appears to be a feasible way of improving the anti-metastasis effect and reducing adverse effects. Here, we established a 2-(dimethylamino) ethyl methacrylate (DEA)-modified N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer–CPT conjugate (P-DEA-CPT) to mediate the mitochondrial accumulation of CPT. The mitochondria-targeted P-DEA-CPT could overcome multiple barriers by quickly internalizing into 4T1 cells, then escaping from lysosome, and sufficiently accumulating in mitochondria. Subsequently, P-DEA-CPT greatly damaged mitochondrial function, leading to the reactive oxide species (ROS) elevation, energy depletion, apoptosis amplification, and tumor metastasis suppression. Consequently, P-DEA-CPT successfully inhibited both primary tumor growth and distant metastasis in vivo. Furthermore, our studies revealed that the mechanism underlying the anti-metastasis capacity of P-DEA-CPT was partially via downregulation of various pro-metastatic proteins, such as hypoxia induction factor-1α (HIF-1α), matrix metalloproteinases-2 (MMP-2), and vascular endothelial growth factor (VEGF). This study provided the proof of concept that escorting CPT to mitochondria via a mitochondrial targeting strategy could be a promising approach for anti-metastasis treatment.
format Online
Article
Text
id pubmed-9331251
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93312512022-07-29 Mitochondria-Targeted Delivery of Camptothecin Based on HPMA Copolymer for Metastasis Suppression Yi, Xiaoli Yan, Yue Shen, Xinran Li, Lian Huang, Yuan Pharmaceutics Article Poor anti-metastasis effects and side-effects remain a challenge for the clinical application of camptothecin (CPT). Mitochondria can be a promising target for the treatment of metastatic tumors due to their vital roles in providing energy supply, upregulating pro-metastatic factors, and controlling cell-death signaling. Thus, selectively delivering CPT to mitochondria appears to be a feasible way of improving the anti-metastasis effect and reducing adverse effects. Here, we established a 2-(dimethylamino) ethyl methacrylate (DEA)-modified N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer–CPT conjugate (P-DEA-CPT) to mediate the mitochondrial accumulation of CPT. The mitochondria-targeted P-DEA-CPT could overcome multiple barriers by quickly internalizing into 4T1 cells, then escaping from lysosome, and sufficiently accumulating in mitochondria. Subsequently, P-DEA-CPT greatly damaged mitochondrial function, leading to the reactive oxide species (ROS) elevation, energy depletion, apoptosis amplification, and tumor metastasis suppression. Consequently, P-DEA-CPT successfully inhibited both primary tumor growth and distant metastasis in vivo. Furthermore, our studies revealed that the mechanism underlying the anti-metastasis capacity of P-DEA-CPT was partially via downregulation of various pro-metastatic proteins, such as hypoxia induction factor-1α (HIF-1α), matrix metalloproteinases-2 (MMP-2), and vascular endothelial growth factor (VEGF). This study provided the proof of concept that escorting CPT to mitochondria via a mitochondrial targeting strategy could be a promising approach for anti-metastasis treatment. MDPI 2022-07-23 /pmc/articles/PMC9331251/ /pubmed/35893790 http://dx.doi.org/10.3390/pharmaceutics14081534 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Yi, Xiaoli
Yan, Yue
Shen, Xinran
Li, Lian
Huang, Yuan
Mitochondria-Targeted Delivery of Camptothecin Based on HPMA Copolymer for Metastasis Suppression
title Mitochondria-Targeted Delivery of Camptothecin Based on HPMA Copolymer for Metastasis Suppression
title_full Mitochondria-Targeted Delivery of Camptothecin Based on HPMA Copolymer for Metastasis Suppression
title_fullStr Mitochondria-Targeted Delivery of Camptothecin Based on HPMA Copolymer for Metastasis Suppression
title_full_unstemmed Mitochondria-Targeted Delivery of Camptothecin Based on HPMA Copolymer for Metastasis Suppression
title_short Mitochondria-Targeted Delivery of Camptothecin Based on HPMA Copolymer for Metastasis Suppression
title_sort mitochondria-targeted delivery of camptothecin based on hpma copolymer for metastasis suppression
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331251/
https://www.ncbi.nlm.nih.gov/pubmed/35893790
http://dx.doi.org/10.3390/pharmaceutics14081534
work_keys_str_mv AT yixiaoli mitochondriatargeteddeliveryofcamptothecinbasedonhpmacopolymerformetastasissuppression
AT yanyue mitochondriatargeteddeliveryofcamptothecinbasedonhpmacopolymerformetastasissuppression
AT shenxinran mitochondriatargeteddeliveryofcamptothecinbasedonhpmacopolymerformetastasissuppression
AT lilian mitochondriatargeteddeliveryofcamptothecinbasedonhpmacopolymerformetastasissuppression
AT huangyuan mitochondriatargeteddeliveryofcamptothecinbasedonhpmacopolymerformetastasissuppression